Game-Changer for Stomach Cancer?

Big news from the ASCO conference: adding the immunotherapy drug durvalumab (Imfinzi) to standard chemo before and after surgery for stomach and GEJ cancers keeps the disease under control longer! In the MATTERHORN trial, this combo cut the risk of cancer coming back or getting worse by 29%. Docs are calling it practice-changing—looks like more patients could be cured with this new approach. If you or someone you know is facing surgery for stomach cancer, this could be a huge deal! #CancerResearch #Immunotherapy #ASCO2025 #Health